Spathopoulou Angeliki, Edenhofer Frank, Fellner Lisa
Department of Genomics, Stem Cell Biology and Regenerative Medicine, Institute of Molecular Biology and Center for Molecular Biosciences Innsbruck, Leopold-Franzens-University Innsbruck, Innsbruck, Austria.
Front Neurol. 2022 Jan 25;12:786835. doi: 10.3389/fneur.2021.786835. eCollection 2021.
Parkinson's disease (PD) is a progressive, neurodegenerative disorder characterized by motor and non-motor symptoms. To date, no specific treatment to halt disease progression is available, only medication to alleviate symptoms can be prescribed. The main pathological hallmark of PD is the development of neuronal inclusions, positive for α-synuclein (α-syn), which are termed Lewy bodies (LBs) or Lewy neurites. However, the cause of the inclusion formation and the loss of neurons remain largely elusive. Various genetic determinants were reported to be involved in PD etiology, including , LRRK2, and . Comprehensive insights into pathophysiology of PD critically depend on appropriate models. However, conventional model organisms fall short to faithfully recapitulate some features of this complex disease and as a matter-of-fact access to physiological tissue is limiting. The development of disease models replicating PD that are close to human physiology and dynamic enough to analyze the underlying molecular mechanisms of disease initiation and progression, as well as the generation of new treatment options, is an important and overdue step. Recently, the establishment of induced pluripotent stem cell (iPSC)-derived neural models, particularly from genetic PD-variants, developed into a promising strategy to investigate the molecular mechanisms regarding formation of inclusions and neurodegeneration. As these iPSC-derived neurons can be generated from accessible biopsied samples of PD patients, they carry pathological alterations and enable the possibility to analyze the differences compared to healthy neurons. This review focuses on iPSC models carrying genetic PD-variants of α-syn that will be especially helpful in elucidating the pathophysiological mechanisms of PD. Furthermore, we discuss how iPSC models can be instrumental in identifying cellular targets, potentially leading to the development of new therapeutic treatments. We will outline the enormous potential, but also discuss the limitations of iPSC-based α-syn models.
帕金森病(PD)是一种以运动和非运动症状为特征的进行性神经退行性疾病。迄今为止,尚无阻止疾病进展的特异性治疗方法,仅可开具缓解症状的药物。PD的主要病理标志是神经元内含物的形成,其α-突触核蛋白(α-syn)呈阳性,这些内含物被称为路易小体(LBs)或路易神经突。然而,内含物形成和神经元丢失的原因在很大程度上仍不清楚。据报道,多种遗传因素参与了PD的病因,包括LRRK2等。对PD病理生理学的全面了解严重依赖于合适的模型。然而,传统的模式生物不足以忠实地重现这种复杂疾病的某些特征,事实上,获取生理组织也受到限制。开发接近人类生理学且动态性足以分析疾病起始和进展的潜在分子机制以及产生新治疗选择的PD复制疾病模型,是重要且早就应该迈出的一步。最近,诱导多能干细胞(iPSC)衍生的神经模型的建立,特别是来自遗传性PD变体的模型,已发展成为一种有前景的策略,用于研究关于内含物形成和神经变性的分子机制。由于这些iPSC衍生的神经元可以从PD患者可获取的活检样本中产生,它们携带病理改变,并能够分析与健康神经元相比的差异。本综述重点关注携带α-syn遗传性PD变体的iPSC模型,这将特别有助于阐明PD的病理生理机制。此外,我们讨论了iPSC模型如何有助于识别细胞靶点,这可能会导致新治疗方法的开发。我们将概述其巨大潜力,但也会讨论基于iPSC的α-syn模型的局限性。